SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to significant price movement and high trading volume, sparking discussions about a potential short squeeze. The community is actively debating entry points, profit-taking strategies, and whether the stock will continue its upward trajectory, drawing comparisons to other high-flying stocks. Some traders are pointing to the company's low float and recent focus on AI-powered robotics as potential catalysts for continued momentum.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim data from its Phase 2b trial, showing promising results in brain metastases imaging, with the community actively discussing the potential for a short squeeze and anticipating further details from an upcoming webinar. The stock's high trading volume and significant pre-market gains are fueling speculative interest, despite some concerns about potential pullbacks and short attacks. This surge is also drawing attention to the broader oncology radiopharmaceutical sector.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential cannabis rescheduling following comments from President Trump, sparking high volatility. The community is debating the likelihood and timing of an executive order, with some anticipating a short squeeze, while others express skepticism and caution against "pump and dump" schemes. Overall, the discussion reflects a mix of hope and uncertainty surrounding the future of cannabis regulation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with the community citing overall negative sentiment towards AI as a key factor despite the company's prior deal with Microsoft. Some traders point to potential tax-loss harvesting and broader market concerns as contributing to the recent price action. Discussions also involve speculation about future catalysts and whether current levels represent a buying opportunity or further downside risk.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as community members discuss the company's application to become a bank, potentially expanding its services to include small business loans and savings accounts.  Some see this as a game-changer with Federal Reserve backing and potential for long-term growth, while others express concern about a possible shift to a bank-hybrid multiple. Discussions also include the potential impact on revenue streams and comparisons to other financial institutions.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to chatter around its low float and potential for a significant price surge, with some comparing it to other recent low-float runners. Discussions also involve the company's fundamentals, potential news catalysts, and high borrow rate, leading to speculation about a possible short squeeze. Some traders are moving profits from other stocks into CLIK, anticipating a substantial upward movement.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest a significant EV write-down and a strategic shift towards hybrid vehicles, which is being interpreted by some as a pragmatic move to focus on profitability and align with current market demand. The community is actively discussing the implications of this shift, with debates around whether it signals a retreat from EVs or a necessary adjustment in a challenging market landscape. Amidst the EV strategy recalibration, analysts are weighing in, setting price targets and evaluating Ford's potential to capitalize on policy shifts favoring domestic production.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending amid discussions around its correlation to Bitcoin's price movements and the broader crypto market, with community members debating its potential as a long-term investment. Some traders are eyeing specific price levels for potential entries or exits, while others are speculating on upcoming announcements and their impact on the stock. Additionally, there's some chatter about potential partnerships and integrations that could drive future growth.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is surging amid reports that an executive order to reclassify marijuana could be signed soon, potentially as early as this week. The community is buzzing about the implications of rescheduling for tax relief, research, and institutional investment, while also closely watching for official confirmation and potential market reactions. Some traders express caution due to past disappointments in the sector, while others see this as the start of a major upward trend.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending amid discussions about its valuation and potential acquisitions, with community members weighing the impact of AI on its business model. Some investors express frustration with the stock's recent performance despite strong earnings, while others see it as an undervalued AI play with long-term growth potential. The community is also closely watching for a potential stock split and its impact on the share price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold

Wall Street Zen upgraded Omeros from a "sell" rating to a "hold" rating in a report on Saturday...

Omeros (NASDAQ:OMER) Trading Down 5.1% - Here's What Happened

Omeros (NASDAQ:OMER) Stock Price Down 5.1% - What's Next...

Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports...

Omeros (NASDAQ:OMER) Stock Price Up 8.2% - Still a Buy?

Omeros (NASDAQ:OMER) Trading 8.2% Higher - What's Next...

Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Monday...

<ul class="summary-bullets"><li>Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.</li><li>The company retired its senior loan and expects the remaining cash to extend its runway.</li><li>Traders say the FDA decision on Narsoplimab is now the key market catalyst.</li></ul><p>Omeros Corporation&nbsp;(OMER) said on Monday it has completed its asset sale and licensing agreement with Novo Nordisk for Zaltenibart, an experimental drug being developed for rare immune-related blood and kidney disorders. The transaction includes up to $2.1 billion in potential payments.</p><p>OMER stock traded in the green at the time of writing.&nbsp;</p><h2 class="st-heading-2"><strong>Terms Of The Deal</strong></h2><p>Omeros received $240 million upfront at closing and could earn up to $340 million in early milestones. The agreement grants Novo Nordisk global rights to Zaltenibart and its intellectual property, with total potential value reaching $2.1 billion through future development and commercial milestones. Omeros will also receive tiered royalties on net sales.</p><h2 class="st-heading-2"><strong>Immune Drug Targets Severe Rare Diseases</strong></h2><p>Zaltenibart, formerly OMS906, is a clinical-stage monoclonal antibody that blocks MASP-3, the immune trigger that switches on the alternative complement pathway. The drug is designed to calm an overactive immune response while preserving the body’s main infection-fighting mechanisms. Potential applications include paroxysmal nocturnal hemoglobinuria and several complement-driven kidney disorders. Novo Nordisk said the acquisition strengthens its position in rare immunological diseases.</p><h2 class="st-heading-2"><strong>Upfront Proceeds Slash Debt And Extend Cash Runway</strong></h2><p>Omeros used part of the upfront payment to fully repay its $67.1 million senior secured term loan, including premiums and interest, resulting in the release of all related covenants. The company expects remaining proceeds to cover repayment of its $17.1 million 2026 Convertible Notes and fund more than a year of operations, including preparations for a potential U.S. launch of its MASP-2 inhibitor Narsoplimab. The company continues to advance additional complement-system candidates, including OMS1029 and OMS527.</p><h2 class="st-heading-2"><strong>Stocktwits Users Warn Of FDA-Driven Swings</strong></h2><p>On Stocktwits, Omeros drew ‘bullish’ retail sentiment with ‘normal’ message volume, while Novo Nordisk saw ‘bearish’ sentiment on ‘low’ volume.</p><figure class="image"><img style="aspect-ratio:971/144;" src="https://news.stocktwits-cdn.com/omer_ss_png_4011ca93db.webp" alt="omer ss.png" width="971" height="144"><figcaption>OMER sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:970/144;" src="https://news.stocktwits-cdn.com/nvo_ss_png_d0f2e79132.webp" alt="nvo ss.png" width="970" height="144"><figcaption>NVO sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><p>One user noted that the announcement appeared mostly priced in around $10 and said the stock now hinges on a potential FDA approval for Zaltenibart due Dec.26, calling it a "pure binary event" that could swing shares 30%–50% either way over the next few weeks.</p><p><stembedurl>https://stocktwits.com/WinstonWolfff/message/637795055</stembedurl></p><p>Another user said, “This deal was known for a long time already. What did you expect? Narsoplimabs FDA approval this month is the moneyball.”&nbsp;</p><p><stembedurl>https://stocktwits.com/Iceman89/message/637792822</stembedurl></p><p><a href="https://stocktwits.com/symbol/OMER">Omeros’ stock</a> has declined nearly 2% so far in 2025, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> fell about 42% over the same period.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.

Equity

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906...

Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving Average - Here's Why

Omeros (NASDAQ:OMER) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened...

Omeros (NASDAQ:OMER) Shares Down 5.6% - Should You Sell?

Omeros (NASDAQ:OMER) Shares Down 5.6% - Here's What Happened...

Omeros (NASDAQ:OMER) Stock Price Up 8.1% - Time to Buy?

Omeros (NASDAQ:OMER) Shares Up 8.1% - Here's What Happened...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corp